Blurbs

Analysts Offer Insights on Healthcare Companies: Medios AG (OtherMEDOF), Spectrum Pharmaceuticals (SPPI) and Fortress Biotech (FBIO)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Medios AG (MEDOFResearch Report), Spectrum Pharmaceuticals (SPPIResearch Report) and Fortress Biotech (FBIOResearch Report) with bullish sentiments.

Medios AG (MEDOF)

Deutsche Bank analyst Michael Kuhn maintained a Buy rating on Medios AG today and set a price target of EUR50.00. The company’s shares closed last Monday at $50.00, equals to its 52-week high of $50.00.

According to TipRanks.com, Kuhn is ranked #7560 out of 8019 analysts.

Currently, the analyst consensus on Medios AG is a Strong Buy with an average price target of $47.92, representing a 72.6% upside. In a report released yesterday, Warburg Research also maintained a Buy rating on the stock with a EUR50.00 price target.

See the top stocks recommended by analysts >>

Spectrum Pharmaceuticals (SPPI)

In a report released today, Edward White from H.C. Wainwright reiterated a Buy rating on Spectrum Pharmaceuticals, with a price target of $10.00. The company’s shares closed last Thursday at $1.21.

According to TipRanks.com, White ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -15.9% and a 31.3% success rate. White covers the Healthcare sector, focusing on stocks such as Karyopharm Therapeutics, Silverback Therapeutics, and Allena Pharmaceuticals.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Spectrum Pharmaceuticals with a $6.00 average price target, a 380.0% upside from current levels. In a report released today, JMP Securities also reiterated a Buy rating on the stock with a $4.00 price target.

Fortress Biotech (FBIO)

H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Fortress Biotech today and set a price target of $10.00. The company’s shares closed last Thursday at $1.29.

According to TipRanks.com, Pantginis has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -20.3% and a 29.8% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Lineage Cell Therapeutics, and Actinium Pharmaceuticals.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Fortress Biotech with a $8.80 average price target, representing a 621.3% upside. In a report issued on August 4, Ladenburg Thalmann & Co. also initiated coverage with a Buy rating on the stock with a $6.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on MEDOF:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More
Videos